sever
studi
shown
reduc
efficaci
influenza
vaccin
elderli
compar
young
adult
studi
evalu
immunogen
protect
efficaci
commerci
avail
inactiv
influenza
vaccin
fluzon
young
adult
age
mice
mice
administ
singl
doubl
immun
fluzon
without
cpg
challeng
intranas
viru
doubl
immun
fluzon
adjuv
cpg
elicit
highest
level
protect
young
adult
mice
associ
increas
influenza
specif
igg
elev
hai
titr
reduc
viral
titr
lung
inflamm
contrast
vaccin
schedul
provid
fulli
protect
immun
young
adult
mice
confer
limit
protect
age
mice
antigen
present
cell
age
mice
found
less
respons
vitro
stimul
fluzon
cpg
may
partial
explain
result
data
support
studi
shown
limit
effect
influenza
vaccin
elderli
provid
import
inform
relev
design
immunogen
vaccin
age
group
influenza
viru
season
viru
affect
individu
us
worldwid
year
risk
complic
includ
young
children
pregnant
women
asthma
suffer
immun
compromis
individu
elderli
elderli
account
hospitalis
influenza
associ
mortal
help
reduc
sever
outcom
public
health
author
recommend
individu
receiv
yearli
influenza
vaccin
howev
sever
clinic
trial
cohort
studi
report
low
rate
vaccin
efficaci
elderli
judg
statist
signific
reduct
influenza
associ
hospitalis
rate
seroconvers
post
vaccin
singl
factor
identifi
explain
lower
vaccin
efficaci
elderli
thought
variou
agerel
defici
immun
respons
contribut
human
anim
studi
known
age
associ
decreas
respons
innat
immun
stimuli
abnorm
product
variou
cytokin
chemokin
growth
factor
addit
immun
cell
older
subject
number
signal
defect
slower
rate
dendrit
cell
migrat
activ
compromis
antigen
present
furthermor
antibodi
product
antibodi
halflif
diminish
age
avail
tcell
repertoir
diminish
due
thymic
involut
well
number
total
naiv
tcell
b
lymphocyt
elderli
factor
like
account
decreas
vaccin
respons
older
individu
sinc
vaccin
reli
fulli
function
immun
system
gener
protect
immun
memori
human
murin
studi
adjuv
increas
antigen
dose
use
gener
better
vaccin
respons
influenza
vaccin
administ
squalen
base
adjuv
gener
higher
seroprotect
rate
peopl
fluzon
highdos
vaccin
formul
made
sanofi
pasteur
contain
four
time
activ
antigen
content
convent
vaccin
receiv
young
adult
increas
seroconvers
rate
elderli
pica
et
al
also
show
higher
dose
live
attenu
influenza
vaccin
necessari
induc
protect
immun
age
mice
compar
young
adult
mice
also
mice
administ
alum
poli
c
influenza
vaccin
substanti
increas
surviv
older
anim
use
replic
incompet
vaccin
vector
deriv
venezuelan
equin
enceph
viru
carri
influenza
transgen
protect
age
mice
lethal
homolog
heterolog
influenza
challeng
find
indic
despit
age
associ
immun
atrophi
possibl
partial
rescu
vaccin
efficaci
elderli
augment
innat
immun
respons
either
higher
antigen
dose
costimul
prime
use
adjuv
studi
compar
influenza
vaccin
respons
commerci
avail
inactiv
influenza
vaccin
fluzon
fz
report
effect
coadminist
well
character
adjuv
cpg
young
adult
age
mice
show
mous
model
efficaci
fluzon
age
mice
lower
young
adult
mice
cpg
coadministr
significantli
improv
vaccin
efficaci
young
adult
age
mice
young
adult
week
middl
age
month
male
femal
purchas
jackson
laboratori
bar
harbor
mice
age
hous
month
old
purchas
nation
institut
age
nia
throughout
text
young
young
adult
refer
week
old
mice
agedold
refer
month
old
mice
group
mice
use
test
groupcondit
ethic
statement
experi
perform
accord
guidelin
institut
anim
care
use
committe
univers
massachusett
medic
school
recommend
guid
care
use
laboratori
anim
institut
laboratori
anim
resourc
nation
research
council
nation
academi
scienc
institut
anim
care
use
committe
umass
medic
school
approv
anim
protocol
use
studi
monitor
daili
infect
surviv
weight
loss
mice
bled
period
monitor
antibodi
product
use
standard
facial
vein
bleed
protocol
mice
sacrif
ethic
consider
lost
origin
bodi
weight
state
approv
protocol
euthanasia
asphyxi
co
use
effort
made
minim
suffer
unexpect
death
observ
infect
weight
loss
chart
show
averag
weight
loss
anim
standard
error
fluzon
inactiv
vaccin
sanofi
pasteur
contain
ha
protein
virus
mice
receiv
high
vaccin
dose
correspond
total
ha
protein
viru
strain
fluzon
vaccin
mice
receiv
one
four
vaccin
formul
fluzon
alon
fz
fz
steril
pb
fluzon
cpg
fzcpg
fz
cpg
pb
cpg
cpg
cpg
pb
pb
alon
pb
administ
intramuscular
vaccin
caudal
thigh
muscl
cpg
purchas
invivogen
catno
sequenc
cell
cultur
suspens
singl
cell
organ
homogen
wash
fb
first
follow
fac
buffer
sodium
azid
incub
titrat
amount
antibodi
fitc
alexafluor
apc
mhcii
pacif
blue
percp
fitc
bd
bioscienc
ebiosci
san
diego
ca
addit
minut
cell
fix
bd
stabil
bd
bioscienc
analysi
data
collect
bd
equip
diva
cs
softwar
bd
bioscienc
analyz
use
flowjo
version
lung
homogen
freezethaw
three
time
centrifug
g
supernat
titrat
doubl
dilut
madin
darbi
canin
kidney
mdck
cell
monolay
flat
bottom
well
plate
incub
hour
sampl
overlaid
methylcellulos
incub
hour
cell
monolay
fix
wash
stain
crystal
violet
solut
visual
plaqu
infecti
unit
enumer
light
microscopi
total
plaqu
form
unit
per
lung
quantifi
number
plaqu
dilut
factor
total
volum
lung
homogen
bone
marrow
deriv
macrophag
bmm
dendrit
cell
bmdc
gener
describ
previous
briefli
femor
bone
harvest
either
young
adult
week
age
month
mice
wash
ethanol
medullar
pulp
wash
steril
rpmi
medium
rbc
lyse
wash
cell
suspens
split
plate
one
plate
differenti
macrophag
cultur
cell
line
condit
media
day
dendrit
cell
med
mhcii
hi
induc
cultur
gmcsf
enrich
fb
medium
day
vitro
stimul
cell
stimul
cpg
invivogen
andor
fluzon
hr
level
cell
cultur
medium
detect
use
commerci
elisa
kit
ebiosci
san
diego
ca
assay
run
duplic
result
shown
mean
valu
repres
separ
experi
igg
detect
microtit
plate
coat
uv
inactiv
influenza
overnight
plate
wash
block
bsapb
sera
immun
mice
ad
incub
hr
room
temperatur
plate
wash
incub
goat
antimous
iggperoxidas
conjug
millipor
temecula
ca
min
room
temperatur
dilut
bsapb
wash
bound
antibodi
detect
plate
incub
tmb
peroxidis
substrat
kpl
gaithersburg
md
dark
minut
reaction
stop
hcl
plate
read
correct
absorb
valu
obtain
sera
mice
subtract
valu
convert
rel
au
hai
assay
two
fold
serial
dilut
heat
inactiv
sera
vaccin
mice
control
mix
viru
incub
min
room
temperatur
equal
volum
chicken
red
blood
cell
crbc
suspens
ad
well
incub
min
room
temperatur
sampl
run
duplic
well
ubottom
well
plate
reciproc
highest
dilut
sera
success
inhibit
crbc
agglutin
defin
hai
titr
serum
sampl
use
graphpad
prism
softwar
perform
nonparametr
statist
analysi
across
group
interest
signific
set
p
cpg
adjuv
improv
efficaci
fluzon
vaccin
challeng
young
adult
mice
group
young
adult
mice
week
n
vaccin
commerci
influenza
vaccin
fluzon
fz
analysi
serum
week
post
vaccin
show
specif
igg
detect
howev
hemagglutin
inhibit
activ
hai
observ
tabl
challeng
influenza
viru
mice
experienc
weight
loss
similar
unvaccin
control
fig
mortal
fig
want
investig
whether
well
character
innat
immun
agonist
cpg
could
improv
immunogen
efficaci
fz
model
four
week
immun
young
adult
mice
immun
fzcpg
specif
igg
titr
time
greater
compar
fz
alon
tabl
detect
hai
activ
equival
fold
increas
post
vaccin
hai
tabl
increas
serum
igg
hai
activ
associ
decreas
peak
weight
loss
follow
infect
follow
full
recoveri
fig
improv
clinic
score
judg
increas
activ
less
fur
ruffl
data
shown
furthermor
mortal
unvaccin
unadjuv
fz
group
reach
follow
infect
compar
adjuv
fzcpg
group
fig
cpg
adjuv
fail
improv
efficaci
fluzon
vaccin
challeng
age
mice
similar
young
adult
mice
age
mice
month
n
vaccin
fz
posit
igg
titr
week
immun
compar
unvaccin
mice
detect
hai
activ
tabl
howev
unlik
young
adult
mice
addit
cpg
adjuv
fzcpg
show
either
increas
influenza
viru
iav
specif
igg
titr
hai
activ
compar
fz
alon
tabl
vaccin
age
mice
show
slightli
lower
weight
loss
time
point
compar
unvaccin
control
follow
influenza
infect
fig
despit
vaccin
unvaccin
age
mice
succumb
infect
mortal
group
fig
sinc
adjuv
vaccin
partial
protect
young
adult
mice
ineffect
prevent
influenza
mortal
age
mice
confirm
age
relat
differ
influenza
vaccin
efficaci
seen
young
age
human
subject
could
model
mice
observ
addit
cpg
increas
efficaci
fz
young
age
mice
cpg
shown
act
adjuv
stimul
innat
respons
antigen
present
cell
apc
first
encount
vaccin
previou
work
alreadi
shown
releas
compromis
vitro
respons
influenza
viru
infect
age
mice
similarli
mhc
class
ii
express
lower
respons
iav
cell
older
adult
stimul
bone
marrow
deriv
macrophag
bmm
dendrit
cell
bmdc
young
adult
age
mice
vitro
fz
fzcpg
examin
product
mhc
class
ii
cell
surfac
express
fig
bmm
young
adult
mice
upregul
mhc
class
ii
respons
fz
fzcpg
minim
regul
cpg
alon
fig
level
low
stimul
fz
alon
significantli
boost
presenc
cpg
fig
contrast
bmm
age
mice
compar
low
mhc
class
ii
regul
respons
fz
detect
regul
presenc
cpg
fig
interestingli
product
similar
bmm
young
adult
age
mice
fig
bmdc
young
adult
mice
also
respons
activ
fz
cpg
alon
fzcpg
show
strong
regul
mhc
class
ii
releas
fig
highest
concentr
measur
cell
stimul
fzcpg
fig
minim
mhcii
regul
bmdc
deriv
age
mice
fig
addit
signific
reduct
fzcpg
sampl
compar
bmdc
young
adult
mice
fig
taken
togeth
found
apc
deriv
age
mice
less
activ
stimul
vitro
either
fz
fzcpg
compar
cell
young
adult
mice
previou
experi
demonstr
coadministr
cpgfz
improv
antibodi
respons
protect
iav
young
adult
age
mice
want
investig
whether
addit
second
vaccin
would
add
benefit
young
adult
mice
lead
protect
age
mice
young
adult
mice
vaccin
fz
alon
fzcpg
week
week
challeng
viru
data
indic
doubl
cpg
adjuv
immun
fzcpg
young
adult
mice
fulli
protect
iav
associ
weight
loss
mortal
fig
convers
group
receiv
two
immun
fz
alon
still
experienc
substanti
weight
loss
group
mortal
four
week
primari
immun
young
adult
mice
fzcpg
group
significantli
higher
level
igg
compar
fz
alon
consist
find
second
immun
group
fzcpg
fz
compar
level
iavspecif
igg
howev
hai
antibodi
level
two
time
higher
adjuv
vs
nonadjuv
group
vs
tabl
next
want
determin
benefit
relat
immun
second
dose
young
adult
mice
could
seen
age
mice
two
separ
experi
age
mice
vaccin
week
prior
challeng
ident
manner
young
adult
mice
number
age
mice
avail
us
limit
compar
protect
vaccin
schedul
fzcpg
young
adult
age
mice
fig
show
age
mice
within
vaccin
group
show
decreas
bodi
mass
loss
follow
infect
result
reduc
weight
loss
recoveri
thereaft
howev
mice
show
degre
weight
loss
overal
group
surviv
fig
thu
vaccin
formul
immun
schedul
result
symptomless
asymptomat
infect
young
adult
mice
gave
modest
level
protect
age
mice
benefit
may
due
cell
mediat
respons
induc
vaccin
sinc
hai
activ
detect
one
main
caus
influenza
associ
morbid
immunopatholog
mediat
larg
influx
neutrophil
late
stage
viral
clearanc
fig
show
young
adult
mice
immun
twice
fzcpg
reduc
influx
neutrophil
present
lung
day
post
infect
compar
unvaccin
mice
mice
vaccin
twice
fz
alon
p
reduct
lung
neutrophilia
gener
sign
reduc
local
inflamm
immunopatholog
vaccin
group
higher
percentag
cell
present
lung
infect
rel
unvaccin
control
shown
howev
mice
immun
twice
fzcpg
significantli
higher
percentag
tcell
lung
follow
infect
fig
final
assess
viral
burden
lung
found
mice
immun
twice
fzcpg
lower
viral
titr
compar
mice
immun
twice
fz
unvaccin
control
fig
sever
studi
demonstr
limit
efficaci
inactiv
influenza
vaccin
elderli
individu
compar
younger
adult
although
reduc
vaccin
efficaci
elderli
gener
attribut
immunosenesc
mechan
lead
phenomenon
fulli
understood
studi
use
mous
model
analyz
dispar
efficaci
split
viru
inactiv
influenza
vaccin
young
adult
age
mice
furthermor
investig
whether
vaccin
efficaci
could
improv
age
mice
coadministr
cpg
adjuv
young
adult
mice
vaccin
fluzon
cpg
prior
iav
challeng
show
clear
benefit
regard
clinic
symptom
activ
fur
ruffl
weight
loss
mortal
compar
unvaccin
mice
young
adult
mice
asymptomat
protect
liveviru
challeng
second
dose
fluzon
cpg
associ
increas
influenza
specif
igg
elev
hai
titr
reduc
viral
titr
lung
inflamm
contrast
benefit
modest
age
mice
immun
protocol
without
adjuv
result
poorer
protect
age
compar
young
adult
mice
strikingli
immun
schedul
fzcpg
dose
confer
full
protect
young
adult
mice
result
partial
protect
surviv
hai
activ
age
mice
apc
older
mice
show
diminish
respons
fz
alon
fzcpg
may
part
account
low
vaccin
efficaci
possibl
age
mice
higher
suscept
iav
young
mice
would
difficult
extric
increas
suscept
diminish
immun
respons
group
found
similar
low
respons
purifi
ha
cpg
age
human
interestingli
found
follow
adjuv
vaccin
young
adult
age
mice
develop
similar
amount
antiinfluenza
specif
igg
serum
sera
young
adult
mice
test
posit
hai
assay
suggest
perhap
antibodi
qualiti
may
compromis
older
mice
studi
report
antibodi
age
individu
shorter
lifespan
lower
affin
due
limit
sera
age
mice
assess
influenzaspecif
igg
isotyp
function
antibodi
adcc
cdl
etc
sera
vaccin
young
adult
age
mice
futur
studi
would
desir
expand
panel
antibodi
isotyp
function
may
reveal
age
associ
differ
influenzaspecif
igg
function
though
result
strike
young
adult
mice
data
show
modest
benefit
two
dose
immun
regimen
use
adjuv
influenza
vaccin
age
mice
result
consist
medium
size
trial
shown
adjuv
influenza
vaccin
fluad
much
stronger
immunogen
patient
year
old
gener
higher
antiiav
titr
post
vaccin
faster
seroconvers
time
similarli
adjuv
fluad
induc
higher
hai
titr
longer
antibodi
persist
infant
young
children
becom
clear
vaccin
strategi
design
test
approv
young
adult
cohort
may
compar
result
elderli
approv
inactiv
influenza
vaccin
us
contain
adjuv
data
studi
other
suggest
may
requir
achiev
adequ
protect
level
elderli
addit
context
new
pandem
strain
prior
immun
crossreact
full
protect
may
requir
doubl
immun
addit
vaccin
adjuv
